Peter S. Hammerman,Martin L. Sos,Alex H. Ramos,Chunxiao Xu,Amit Dutt,Wenjun Zhou,Lear E. Brace,Brittany A. Woods,Wenchu Lin,Jianming Zhang,Xianming Deng,Sang Min Lim,Stefanie Heynck,Martin Peifer,Jeffrey R. Simard,Michael S. Lawrence,Robert C. Onofrio,Helga B. Salvesen,Danila Seidel,Thomas Zander,Johannes M. Heuckmann,Alex Soltermann,Holger Moch,Mirjam Koker,Frauke Leenders,Franziska Gabler,Silvia Querings,Sascha Ansén,Elisabeth Brambilla,Christian Brambilla,Philippe Lorimier,Odd Terje Brustugun,Åslaug Helland,Iver Petersen,Joachim H. Clement,Harry Groen,Wim Timens,Hannie Sietsma,Erich Stoelben,Jürgen Wolf,David G. Beer,Ming Sound Tsao,Megan Hanna,Charles Hatton,Michael J. Eck,Pasi A. Janne,Bruce E. Johnson,Wendy Winckler,Heidi Greulich,Adam J. Bass,Jeonghee Cho,Daniel Rauh,Nathanael S. Gray,Kwok-Kin Wong,Eric B. Haura,Roman K. Thomas,Matthew Meyerson

Abstract:AbstractAlthough genomically targeted therapies have improved outcomes for patients with lung adenocarcinoma, little is known about the genomic alterations that drive squamous cell cancer (SCC) of the lung. Sanger sequencing of the tyrosine kinome identified mutations in the DDR2 kinase gene in 3.8% of lung SCCs and cell lines. Lung SCC cell lines harboring DDR2 mutations were selectively killed by knockdown of DDR2 by RNA interference or by treatment with the multitargeted kinase inhibitor dasatinib. Tumors established from a DDR2 mutant cell line were sensitive to dasatinib in xenograft models. Expression of mutated DDR2 led to cellular transformation that was blocked by dasatinib. A patient with lung SCC that responded to dasatinib and erlotinib treatment harbored a DDR2 kinase domain mutation. These data suggest that gain-of-function mutations in DDR2 are important oncogenic events and are amenable to therapy with dasatinib. Because dasatinib is already approved for use, these findings could be used to rapidly generate clinical trials.Significance: DDR2 mutations are present in 4% of lung SCCs, and DDR2 mutations are associated with sensitivity to dasatinib. These findings provide a rationale for designing clinical trials with the FDA-approved drug dasatinib in patients with lung SCCs. Cancer Discovery; 1(1); 78–89. ©2011 AACR.Read the Commentary on this article by Ohashi and Pao, p. 23This article is highlighted in the In This Issue feature, p. 4

Supplementary Figure Legends 1-7 from Mutations in the <i>ddr2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Supplementary Figures 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Supplementary Table 1 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Data from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Interview with Dr. Meyerson from Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Supplementary Materials and Figure Legends 1-4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure 2 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure 1 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Figure Legends 1-7 from Mutations in the &lt;i&gt;ddr2&lt;/i&gt; Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer